Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.

Rheumatology (Oxford, England) - 1 Jul 1999

Naughton M A, Battaglia E, O'Brien S, Walport M J, Botto M

Abstract excerpt

OBJECTIVE: To determine whether the presence of polymorphisms associated with reduced or absent activity of thiopurine methyltransferase (TPMT), an enzyme involved in azathioprine metabolism, can predict side-effects, particularly myelosuppression, in patients taking this drug. METHODS: The TPMT genotype was determined in 120 patients with systemic lupus erythematosus (SLE) together with 15 patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azathioprine
Share to Immunosuppressive Agents

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Inflammatory Bowel Diseases

Share to Lupus Erythematosus, Systemic

Share to Methyltransferases

Share to Neutropenia

Share to Polymorphism, Genetic

Share to Predictive Value of Tests

Source

Identifiers

PMID: 10461478
DOI: 10.1093/rheumatology/38.7.640

Genes

TPMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Identification of thiopurine methyltransferase (TPMT) polymorphisms cannot predict myelosuppression in systemic lupus erythematosus patients taking azathioprine.PMID 10461478Read ↗

Assessment of thiopurine methyltransferase enzyme activity is superior to genotype in predicting myelosuppression following azathioprine therapy in patients with inflammatory bowel disease.Semantic proximity Read ↗

Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.Semantic proximity Read ↗

Thiopurine S-methyltransferase polymorphisms and the relationship between the mutant alleles and the adverse effects in systemic lupus erythematosus patients taking azathioprine.Semantic proximity Read ↗

Limitations of extensive TPMT genotyping in the management of azathioprine-induced myelosuppression in IBD patients.Semantic proximity Read ↗

Thiopurine methyltransferase (TPMT) genotyping to predict myelosuppression riskSemantic proximity Read ↗

Thiopurine Methyltransferase Genotype Predicts Therapy-Limiting Severe Toxicity from AzathioprineSemantic proximity Read ↗

Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy.Semantic proximity Read ↗

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease PatientsSemantic proximity Read ↗

Thiopurine S-methyltransferase genotypic analysis in autoimmune bullous diseases.Semantic proximity Read ↗

Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?Semantic proximity Read ↗

Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?Semantic proximity Read ↗

An audit of thiopurine methyltransferase genotyping and phenotyping before intended azathioprine treatment for dermatological conditions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.